Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

928742

registered interest
date	21/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Rare Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to revise the rare disease strategy ahead of the UK leaving the EU.
tabling member constituency	Oxford East
tabling member printed	Anneliese Dodds
uin	156485
answer	answer is ministerial correction date of answer 28/06/2018 answer text <p>With the aim of improving the lives of all those affected by a rare disease, the United Kingdom Government published the UK Strategy for Rare Diseases in 2013, a high-level framework containing 51 commitments which sets out a 7-year strategic vision (2013-2020).</p><p> </p><p>The Government is committed to implementing the Strategy’s commitments and has, in January 2018, published Implementation Plans setting out its actions for England.</p><p> </p><p>The UK Rare Disease Policy Board is the UK-wide body responsible for facilitating the co-ordination of policy development and meeting the commitments set out in the UK Strategy for Rare Diseases. The Strategy is kept under review to take account of new developments including the outcome of negotiations with the European Union.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 28/06/2018 11:20:40 answering member 4067 label Biography information for Steve Brine
tabling member	4657 label Biography information for Anneliese Dodds

928744

registered interest
date	21/06/2018
answering body	Department for Work and Pensions
answering dept id	29
answering dept short name	Work and Pensions
answering dept sort name	Work and Pensions
hansard heading	Maternity Pay
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Work and Pensions, what steps her Department takes to ensure that women are informed of their entitlement to statutory maternity pay at the higher level when they are preparing to go on maternity leave and are on maternity leave.
tabling member constituency	Oxford East
tabling member printed	Anneliese Dodds
uin	156486
answer	answer is ministerial correction date of answer 25/06/2018 answer text <p>Full and clear information about Statutory Maternity Pay is publically available on the GOV.UK website, including the way it is calculated, the levels at which it is payable, and the eligibility criteria. There is also information about maternity leave and a guide to how both operate together.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 25/06/2018 11:50:29 answering member 4495 label Biography information for Kit Malthouse
tabling member	4657 label Biography information for Anneliese Dodds

928755

registered interest
date	21/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Rare Diseases: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of whether NICE's guidance on the drug Orkambi supports his Department's approach of ensuring that NICE appropriately funds new, targeted technologies for the treatment of rare diseases.
tabling member constituency	Oxford East
tabling member printed	Anneliese Dodds
uin	156487
answer	answer is ministerial correction date of answer 28/06/2018 answer text <p>Orkambi was appraised for the treatment of cystic fibrosis by the National Institute for Health and Care Excellence (NICE) in July 2016, but was not recommended. While it was clinically effective, the benefits were not sufficient to justify its considerable cost. NICE’s guidance is scheduled for review in July 2019.</p><p> </p><p>NICE is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments, including for rare diseases, represent an effective use of NHS resources. NICE’s methods and processes for the assessment of drugs have been carefully developed over time and are internationally respected. NICE continues to keep its procedures under periodic review to ensure that they remain effective.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 28/06/2018 14:10:03 answering member 4067 label Biography information for Steve Brine
tabling member	4657 label Biography information for Anneliese Dodds

928830

registered interest
date	21/06/2018
answering body	Ministry of Housing, Communities and Local Government
answering dept id	7
answering dept short name	Housing, Communities and Local Government
answering dept sort name	Housing, Communities and Local Government
hansard heading	Social Rented Housing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Housing, Communities and Local Government, with reference to the letter from the Minister for Housing and Homelessness, reference 3677980 on support for for landlords to offer longer tenancies where they are wanted, whether local authorities will be provided with the flexibility to retain secure tenancies as standard in local Tenancy Strategies, under the responsibilities conveyed by the Housing and Planning Act 2016.
tabling member constituency	Oxford East
tabling member printed	Anneliese Dodds
uin	156488
answer	answer is ministerial correction date of answer 26/06/2018 answer text <p>The Housing and Planning Act 2016 includes provision for regulations to set out the circumstances in which local authorities will have discretion to continue to grant lifetime tenancies.</p> answering member constituency South Derbyshire answering member printed Mrs Heather Wheeler question first answered 26/06/2018 10:24:39 answering member 4053 label Biography information for Mrs Heather Wheeler
tabling member	4657 label Biography information for Anneliese Dodds